SAFETY AND EFFICACY OF MACITENTAN IN ELDERLY PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM SERAPHIN

In SERAPHIN, the endothelin receptor antagonist macitentan reduced morbidity/mortality risk by 45% in PAH patients. Here we explore the efficacy and safety of macitentan in elderly PAH patients in SERAPHIN. SERAPHIN was a multicenter, double-blind, randomized, placebo-controlled, event-driven,